A small study involving Keytruda (pembrolizumab) showed that the cancer drug has been effective in shrinking or removing cancer tumors. With this, the U.S. Food and Drug Administration immediately approved the drug for patients with locally advanced or metastatic urothelial carcinoma.
The Keytruda is the first drug that has been approved for treating tumors that share a certain genetic profile, and thousands of patients are expected to benefit from it every year, according to The New York Times. Even without a control group, or a set of patients that did not receive the drug to compare with, the results are compelling and convincing.
The study, originally released in the Science journal, saw eighty-six patients participating in the trial. Sixty-six of them had tumors that shrank significantly. Among the 66 patients, 18 patients had their tumors disappeared.
Dr. Jack Jacoub, a medical oncologist at MemorialCare Cancer Institute, said that the results of the study, which was published in the journal Science last week, showed the effectiveness of targeting the immune system to treat cancer. This is in contrast to the common classification of cancers based on their location in the body. With pembrolizumab, the cancer cells are unmasked so that the immune system can identify and destroy them.
Keytruda is made by Merck & Co. and costs around $156,000 a year for patients with advanced lung, melanoma and bladder tumors. The study is ongoing, and the drug maker has also begun a trial to pair Keytruda with CTLA4 candidate MK-1308, per FiercePharma.
Merck hosted an encouraging analyst meeting at ASCO last week, and Morgan Stanley remains bullish on growth prospects of its new cancer drug. The Keytruda is the main catalyst for the company’s stock this year, which Zacks Investment Research rated “buy” in a research note published on May 26, according to a report from Smart Stock News.
4 strange trading theories to know about
Following volatile markets has its intricacies, but there are trading theories that may seem out of this world. Here’s a...
For the cannabis industry, big data is the new gold
To make good use of data is never easy, and the challenge can be overwhelming when dealing with big data.
Institutional investors finally step into cryptocurrency market
The cryptocurrency gets a newfound strength thanks to the entry of institutional investors. Will the market gain new footing?
Is AI killing A/B split testing?
Marketers use A/B split testing to help them in decision making, but artificial intelligence can help fine-tune this method. Here’s...
How to boost your business using mobile marketing
People check their smartphones 80 times in one day. Here’s how businesses can reach a wider audience to advertise goods...
Sponsored1 day ago
Harbinger Research Labels PotNetwork a ‘Strong Speculative Buy’
Featured3 days ago
Business MOOCs: Where to learn and their impact in one’s career
Featured2 days ago
World leaders and their famous animal companions
Agriculture3 days ago
Cage-free eggs vs regular eggs: Which is better?
Featured5 days ago
What to emulate in Apple’s business and workplace management
Business2 days ago
Tips on how to smartly use credit cards overseas
Featured4 days ago
Retirement planning: What to know about the current distribution phase
Business3 days ago
Why big data is a game changer for the real estate industry?